Skip to main content
Fig. 1 | BMC Molecular and Cell Biology

Fig. 1

From: Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody

Fig. 1

The CDR3 of EgB4 is substantially shorter than that of other anti-EGFR nanobodies. (Left) Structural alignment of four described anti-EGFR nanobodies showing the difference in CDR3 length. Inset shows the complete EgB4 nanobody. FR: framework region (grey). (Right) Corresponding sequence alignment with residues numbered according to the EgB4 sequence. A sequence alignment following the ImMunoGeneTics (IMGT) numbering is shown in Fig. S2

Back to article page